QNCX
NASDAQQuince Therapeutics Inc.
News25/Ratings10
News · 26 weeks55+43%
2026-04-192026-10-11
Mix3090d
- SEC Filings17(57%)
- Other8(27%)
- Analyst5(17%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.SCHEDULE 13G - IRulya Therapeutics Inc. (0001662774) (Subject)
- ANALYSTRaymond James initiated coverage on Quince Therapeutics with a new price targetRaymond James initiated coverage of Quince Therapeutics with a rating of Outperform and set a new price target of $72.00
- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- PRQuince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary DiseaseCompany common stock to trade on Nasdaq under the symbol "IRLA" effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R. Fandrick, Ph.D. Board strengthened with the addition of Catherine Bonuccelli, M.D., Leone Patterson, James Valentine, J.D., M.H.S., and Drayton Wise Cash balance of $116 million as of June 30, 2026 expected to fund operations through the end of 2028, supporting anticipated clinical data readouts from Phase 2 studies of LAM-001 in BOS, PH-ILD, and SAPH SOUTH SAN FRANCISCO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (NASDAQ:QNCX), a clinical stage biopharmaceu
- SECSEC Form S-8 filed by Quince Therapeutics Inc.S-8 - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form DEFA14A filed by Quince Therapeutics Inc.DEFA14A - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- ANALYSTRodman & Renshaw initiated coverage on Quince Therapeutics with a new price targetRodman & Renshaw initiated coverage of Quince Therapeutics with a rating of Buy and set a new price target of $70.00
- ANALYSTQuince Therapeutics upgraded by Citizens with a new price targetCitizens upgraded Quince Therapeutics from Mkt Perform to Mkt Outperform and set a new price target of $77.00
- PRQuince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (NASDAQ:QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious, underserved diseases, today announced that it will host a virtual key opinion leader (KOL) event on Monday, September 28, 2026 from 12:30-2:00 PM ET. The event will feature PH-ILD experts Aaron B. Waxman, MD, PhD (Brigham and Women's Hospital) and Paul Yu, MD, PhD (Massachusetts General Hospital), as well as BOS expert Steven Hays, MD (UCSF Health) to discuss the current treatment landscape and unmet need for PH-ILD and BOS as well as the role for LAM-001 as a potenti
- SECQuince Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Leadership Update8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- PRQuince Therapeutics to Participate in September 2026 Investor ConferencesSOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (NASDAQ:QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that senior management will participate in the following investor conferences in September 2026: Cantor Global Healthcare Conference: Fireside chat on Wednesday, September 9, 2026 at 2:45 p.m. ET H.C. Wainwright 28th Annual Global Investment Conference: Company presentation available on Monday, September 14, 2026 A webcast of each event will be accessible by visiting the "Events" section on the "Investors" page of Quince’s websi
- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form DEF 14A filed by Quince Therapeutics Inc.DEF 14A - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form EFFECT filed by Quince Therapeutics Inc.EFFECT - Quince Therapeutics, Inc. (0001662774) (Filer)
- ANALYSTCraig Hallum initiated coverage on Quince Therapeutics with a new price targetCraig Hallum initiated coverage of Quince Therapeutics with a rating of Buy and set a new price target of $68.00
- SECQuince Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Quince Therapeutics Inc.SCHEDULE 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)
- SECSEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.SCHEDULE 13G - Quince Therapeutics, Inc. (0001662774) (Subject)
- SECQuince Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- PRQuince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate UpdateCompleted acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027 Closed private placement financing, receiving $115 million in upfront gross proceeds, with potential for up to an additional $83 million upon exercise of warrants (including warrants issued to former Orphai stockholders) Cash and cash equivalents of $116 million as of June 30, 2026, expected to fund operations through the end of 2028 SOUTH SAN FRANCISCO, Calif., Aug. 14, 2026
- SECSEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.SCHEDULE 13G - Quince Therapeutics, Inc. (0001662774) (Subject)
- SECAmendment: SEC Form S-3/A filed by Quince Therapeutics Inc.S-3/A - Quince Therapeutics, Inc. (0001662774) (Filer)
QNCX FAQ
6 questionsWhere does QNCX stock trade?
Quince Therapeutics Inc. (QNCX) is listed on NASDAQ.What sector and industry is QNCX in?
Quince Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Quince Therapeutics Inc. go public?
Quince Therapeutics Inc. (QNCX) completed its IPO in 2019.What are analysts saying about QNCX?
Quince Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Outperform on 2026-10-09. Recent price targets cluster around $400.00.What companies are similar to QNCX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare QNCX side-by-side with any of them on Quantisnow.How can I track QNCX on Quantisnow?
Quantisnow aggregates Quince Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QNCX to receive live email and push alerts on every new disclosure.